Stocks Hitting 52-Week Lows

shares fell 15.66 percent to touch a new 52-week low of $4.18 after the company announced a private offering of $100 million in convertible senior notes.

shares dropped 67.35 percent to touch a new 52-week low of $1.44. Infinity announced plans to cut 21 percent of the workforce. The company also reported that DYNAMO Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib met its primary endpoint.

shares reached a new 52-week low of $13.77 as the company reported that its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines (crow's feet) had failed to meet co-primary and other endpoints.

shares fell 21.62 percent to touch a new 52-week low of $4.93 after the company reported that it has received a Complete Response Letter from the FDA regarding its Apadaz NDA .